Journals and Conferences

BACKGROUND
Lenalidomide, an oral immunomodulatory drug that is similar to thalidomide but has a different safety profile, has clinical activity in relapsed or refractory multiple myeloma.
METHODS… (More)

In a phase 2 open-label study of the novel proteasome inhibitor bortezomib, 54 patients with multiple myeloma who had relapsed after or were refractory to frontline therapy were randomized to receive… (More)

This paper presents a similarity-based approach for estimating the Remaining Useful Life (RUL) in prognostics. The approach is especially suitable for situations in which abundant run-to-failure data… (More)

Carfilzomib, a selective proteasome inhibitor, was approved in 2012 for the treatment of relapsed and refractory multiple myeloma. Safety data for single-agent carfilzomib have been analyzed for 526… (More)

Quinones represent a large and diverse class of antitumor drugs and many quinones are approved for clinical use or are currently undergoing evaluation in clinical trials. For many quinones reduction… (More)

Hurricane Felix passed over the Bermuda testbed mooring on 15 August 1995, providing a unique opportunity to observe the response of the upper ocean to a hurricane. In the vicinity of Bermuda, Felix… (More)